Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) – Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *